scout
|Articles|September 1, 1999

Oncology

  • ONCOLOGY Vol 13 No 9
  • Volume 13
  • Issue 9

Paclitaxel and Radiotherapy:The European Experience in Non–Small-Cell Lung Cancer

The development of effective and well-tolerated combinations of chemotherapy and radiotherapy is of great importance to improve disease-free survival in patients treated for non–small-cell lung cancer. Studies

ABSTRACT: The development of effective and well-tolerated combinations of chemotherapy and radiotherapy is of great importance to improve disease-free survival in patients treated for non–small-cell lung cancer. Studies demonstrate that paclitaxel (Taxol) is highly active in treating metastatic lung cancer. Additionally, in vitro studies show that it is a potent radiosensitization agent. Therefore, studies have been undertaken to evaluate the combination of paclitaxel and radiotherapy in advanced non–small-cell lung cancer. Results of these studies are encouraging, demonstrating that 1-year survival rates of up to 66% and impressive disease-free intervals can be achieved with acceptable toxicities. Further studies are currently being undertaken or planned to confirm these results and to establish the optimal combination of paclitaxel and radiotherapy. [ONCOLOGY 13(4):51-53, 1999]

Internal server error